Iterum Therapeutics Plc (NASDAQ: ITRM) kicked off on Tuesday, up 8.57% from the previous trading day, before settling in for the closing price of $0.7. Over the past 52 weeks, ITRM has traded in a range of $0.61-$3.02.
Annual sales at Healthcare sector company grew by 29.27% over the past five years. While this was happening, its average annual earnings per share was recorded 62.92%. With a float of $43.68 million, this company’s outstanding shares have now reached $44.66 million.
Iterum Therapeutics Plc (ITRM) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Iterum Therapeutics Plc is 2.19%, while institutional ownership is 4.53%. The most recent insider transaction that took place on Aug 08 ’25, was worth 10,854. In this transaction Director of this company bought 15,000 shares at a rate of $0.72, taking the stock ownership to the 235,001 shares.
Iterum Therapeutics Plc (ITRM) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.24 earnings per share (EPS), lower than consensus estimate (set at -0.21) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 62.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.64% during the next five years compared to 29.27% growth over the previous five years of trading.
Iterum Therapeutics Plc (NASDAQ: ITRM) Trading Performance Indicators
Take a look at Iterum Therapeutics Plc’s (ITRM) current performance indicators. Last quarter, stock had a quick ratio of 2.52. For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.86, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.27 in one year’s time.
Technical Analysis of Iterum Therapeutics Plc (ITRM)
Iterum Therapeutics Plc (NASDAQ: ITRM) saw its 5-day average volume 1.03 million, a positive change from its year-to-date volume of 0.62 million. As of the previous 9 days, the stock’s Stochastic %D was 30.76%.
During the past 100 days, Iterum Therapeutics Plc’s (ITRM) raw stochastic average was set at 22.30%, which indicates a significant decrease from 58.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0484 in the past 14 days, which was lower than the 0.0556 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7156, while its 200-day Moving Average is $1.1171. Nevertheless, the first resistance level for the watch stands at $0.8145 in the near term. At $0.8691, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.9071. If the price goes on to break the first support level at $0.7219, it is likely to go to the next support level at $0.6839. Assuming the price breaks the second support level, the third support level stands at $0.6293.
Iterum Therapeutics Plc (NASDAQ: ITRM) Key Stats
The company with the Market Capitalisation of 33.94 million has total of 47,169K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -24,770 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -6,510 K.
